TP53 and breast cancer: By comparing their molecular features such as HER2 gene mutations and copy number alterations and p53 mutation status to those of HER2(+) high-grade breast cancer will demonstrate if there are any differences to better classify the HER2(+) cILCs to guide management of this rare subset of breast cancer to avoid unnecessary treatment and drug toxicity.